Like LABS business in Germany, I see we are "very robust" here today as well. After Germany 'rescheduling', I'm pretty sure Vice President Kamala Harris told us the DEA is next for the U.S. market.
PLEASE, do not forget, LABS is the only FDA approved source in North America for PHARMACEUTICAL CANNABINOID BASED MOLECULES.
Any idea who funded over $80 million CAD on those over "20 strong clinical trials" because the LABS balance sheet has no debt to correlate to it financially.